« No phlebotomies were required to maintain hematocrit <45% in the 6th year of treatment in 81.4% of patients receiving Besremi compared with 60.0% of patients in the control arm (p=0.005).
Depletion of the JAK2V617F alle burden, which may lower the risk of progression to myelofibrosis, was observed in Besremi treated patients; JAK2V617F allele burden <1% at 6 years was achieved in 19/92 (20.7%) patients in the Besremi arm with baseline allele burden >10%. One patient met this threshold in the control arm (1/70 [1.4%]; p=0.0001).
Event-free survival (risk events: disease progression, death and thromboembolic events) over ≥6 years of treatment was significantly higher among Besremi treated patients than the control group.
Conclusion
Long-term Besremi therapy fulfils treatment goals important to patients with PV: a good quality of life as indicated by a low symptom burden and phlebotomy requirement, the potential to influence myelofibrosis risk, and better event-free survival versus Best Available Treatment (BAT). »
20% treated with RoPeg achieving allele burden <1% is lower than I had hoped for, considering the risks vs benefits of Besremi for someone with allele burden slightly over 10%. Would be interested to know if the allele burden was still reduced in the 80% treated with RoPeg, but just not to the <1% range. It does seem to reinforce RoPeg being a superior treatment to HU for allele burden reduction, low symptom burden, and phlebotomy requirement. Thanks for sharing!
Hi Manouche. Thanks for this posting. I agree that for 20% of people it's a great achievement to have a change in the disease itself (as opposed to symptoms). I celebrate for you. That's why I went onto pegylated interferon. However that means there's another 80% (of which I am one), for whom that isn't the case. There hasn't been a lot of information posted on this site about that - maybe it's time to start that thread. I do appreciate the posting. Best wishes.
Hi MPNblog,I’m on the boat of those with 80% with an AB very much above 1%. Nothing to worry about. Changes take times both ways! « The growth of the JAK2V617F allele burden from 0.01% to 1% was found to span almost a decade, while further growth to 33% required approximately 7 year ».
I think it's misleading news because the pegylated interferon alfa formulations (Pegasys & Pegintron) that have been available since the mid-2000's could achieve the same results as could the short acting interferon alfa formulations used in the 1990's:
"It is argued that in 2011, the bulk of evidence for the efficacy and safety of pegylated interferons in treating patients with these neoplasms favors the upfront use of pegylated interferons, the goal being to influence the development of the disease at the molecular level and revert patients to a stage of minimal residual disease/operational cure? instead of progressive clonal evolution, genomic instability and leukemic or myelofibrotic transformation during long-term treatment with hydroxyurea."
Hi Monarch5000,It’s unlikely that all IFN medications can achieve the same results because of the toxicities of the early formulations. In others words, all IFN formulations can potentially lead to an operational cure, but at different rates, because of their various level of toxicities and side effects.
Thanks for the great find. I've been awaiting 6 year data on ContiPV. This image in the abstract shows the numbers nicely and goes to 7 years+ for some.
We're still with "potential to influence myelofibrosis risk". Some Drs still want to see more proof on that, but I'm all in on "potential".
They refer to " defined symptoms". My big one, malaise, is not on many of these lists. But the diff from HU was not that large in any case.
I agree on the INF formulations, early INF is not as relevant for the recent studies. Currently I think Pegasys is the only comparable INF, with a long record as monarch5000 notes. Some here are also tolerating PEG better than Bes.
But I have posted before a plot showing PEG with increasing allele after 5 years, hence my eagerness to see this report that suggests Bes avoids this.
As expected we'll need to await the Euro conference to see more details, ie how the allele responses are sliced, will we see the general trend continuing down for most patients as jmctrek notes or is there a group where the reductions stop/reverse as the PEG report seemed to show?
Hi EPguy, As far as I know, there’s no evidence of an AB increase over time on patients having the same dose of IFN on weekly or bi-monthly injections.
hi m, very interested in results. could you send link to study?my consultant has said to my local health authority to not fund bes as study too small/ results inconclusive. she favours the peg interferon which i cant have, so stuck on hu.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Switch from Besremi to Jakafi
